LBT Innovations Limited engages in the research, development, and commercialization of technologies for the healthcare and laboratory supply markets in Australia and Switzerland.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.12|
|52 Week High||AU$0.071|
|52 Week Low||AU$0.17|
|1 Month Change||-17.86%|
|3 Month Change||9.52%|
|1 Year Change||-8.00%|
|3 Year Change||4.55%|
|5 Year Change||-77.45%|
|Change since IPO||-41.03%|
Recent News & Updates
Is LBT Innovations (ASX:LBT) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Is LBT Innovations (ASX:LBT) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
How Much Is LBT Innovations Limited (ASX:LBT) Paying Its CEO?
Brent Barnes became the CEO of LBT Innovations Limited ( ASX:LBT ) in 2016, and we think it's a good time to look at...
|LBT||AU Medical Equipment||AU Market|
Return vs Industry: LBT underperformed the Australian Medical Equipment industry which returned -6.5% over the past year.
Return vs Market: LBT underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: LBT is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: LBT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
LBT Innovations Limited engages in the research, development, and commercialization of technologies for the healthcare and laboratory supply markets in Australia and Switzerland. The company offers MicroStreak, an automated culture-plate streaking and inoculation system; and Automated Plate Assessment System, a platform technology that automates culture-plate screening and interpretation. It also develops Automated Gram Strain Assessment for the automated interpretation of gram stain image analysis; WoundVue, a technology that uses artificial intelligence to assist clinicians in the assessment and care of chronic wounds; and devices that can detect biofilms in the presence of mammalian tissue.
LBT Innovations Fundamentals Summary
|LBT fundamental statistics|
Is LBT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LBT income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.025|
|Net Profit Margin||-20,742.86%|
How did LBT perform over the long term?See historical performance and comparison
Is LBT Innovations undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate LBT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate LBT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: LBT is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: LBT is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LBT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LBT is good value based on its PB Ratio (1.3x) compared to the AU Medical Equipment industry average (5x).
How is LBT Innovations forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as LBT Innovations has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has LBT Innovations performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LBT is currently unprofitable.
Growing Profit Margin: LBT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LBT is unprofitable, and losses have increased over the past 5 years at a rate of 31.1% per year.
Accelerating Growth: Unable to compare LBT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LBT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: LBT has a negative Return on Equity (-29.18%), as it is currently unprofitable.
How is LBT Innovations's financial position?
Financial Position Analysis
Short Term Liabilities: LBT's short term assets (A$11.6M) exceed its short term liabilities (A$2.6M).
Long Term Liabilities: LBT's short term assets (A$11.6M) exceed its long term liabilities (A$8.2M).
Debt to Equity History and Analysis
Debt Level: LBT's debt to equity ratio (11.8%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if LBT's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LBT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: LBT has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 26.6% each year.
What is LBT Innovations's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LBT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LBT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LBT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LBT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LBT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Brenton John Barnes, also known as Brent, has been the Chief Executive Officer and Director of LBT Innovations Limited since August 08, 2016. Mr. Barnes has been the Managing Director of LBT Innovation...
CEO Compensation Analysis
Compensation vs Market: Brent's total compensation ($USD343.93K) is about average for companies of similar size in the Australian market ($USD302.06K).
Compensation vs Earnings: Brent's compensation has increased whilst the company is unprofitable.
Experienced Management: LBT's management team is considered experienced (4.8 years average tenure).
Experienced Board: LBT's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
LBT Innovations Limited's employee growth, exchange listings and data sources
- Name: LBT Innovations Limited
- Ticker: LBT
- Exchange: ASX
- Founded: 2004
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$33.248m
- Shares outstanding: 289.12m
- Website: https://www.lbtinnovations.com
- LBT Innovations Limited
- 16 Anster Street
- South Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 15:25|
|End of Day Share Price||2021/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.